EMEA-001006-PIP03-16
Key facts
Invented name |
|
Active substance |
nintedanib
|
Therapeutic area |
Oncology
|
Decision number |
P/0124/2017
|
PIP number |
EMEA-001006-PIP03-16
|
Pharmaceutical form(s) |
Capsule, soft
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Boehringer Ingelheim International GmbH
Tel. +49 6132 778271 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|